OCULAR THERAPEUTIX, INC (OCUL) research
OCULAR THERAPEUTIX, INC- Sector
- Pharmaceuticals
- Last price
- $9.99
- As of
OCULAR THERAPEUTIX, INC (OCUL): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-03.
As of . Source: SEC EDGAR filings for OCUL. Method and limitations.
Share the OCUL intelligence card
See OCUL live in the terminal
Track OCUL's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live OCUL terminal, freeActive signals for OCUL
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 67% of OCUL (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +84% to OCUL (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +270% to OCUL (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +318% to OCUL (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 67% of OCUL (2026Q2)
FREE, NO ACCOUNT
Every signal on OCUL, as it fires
You are seeing 5 of 21 signals recorded on OCUL since 2026-06-03.
The five above all landed on 2026-09-06. The other 16 were recorded on 4 other days. 17 of the 21 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in OCUL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 67576A100 · 2026Q2 | $32.3M | 0.04% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 67576A100 · 2026Q2 | $12M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 67576A100 · 2026Q2 | $3.7M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 67576A100 · 2026Q2 | $3M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 67576A100 · 2026Q2 | $1.2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, OCUL
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
OCUL against its peers
OCUL's operating margin of -519.8% ranks in the 12th percentile of 19 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | OCUL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 52.0M USD | 638M USD | 16 | 21 |
| Gross margin | n/a | 53.3% | n/a | 7 |
| Operating margin | -519.8% | 8.5% | 13 | 19 |
| Net margin | -511.9% | 0.6% | 12 | 20 |
| Return on equity | -40.6% | -9.3% | 39 | 21 |
| P / E | n/a | 14.9x | n/a | 10 |
Peers (25): NKTR, SUPN, BHC, TRVI, HRMY, GPCR, NUVB, ANIP, INVA, OGN, AMLX, TARS, XERS, PAHC, OMER, ANRO, ALMS, AMPH, PCRX, LQDA, AMRX, ESPR, ACRS, COLL, AXSM. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (OCUL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more OCUL signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to OCULand get the insider, 13F, options, and confluence read in one view.